Figure 5.
Figure 5. Association of catalase or GPX levels with IGHV status, BCR signaling, and clinical behavior. (A) Expression levels of catalase or GPX in mutated (M) and unmutated (UM) IGHV CLL (n = 26). *P ≤ .05; **P ≤ .01 (B) Association between phosphorylation responses to BCR modulation and catalase or GPX expression levels. BCR signaling in response to anti-IgM stimulation was measured as the log2-fold change of ERK1/2 phosphorylation between anti-IgM-modulated and unmodulated conditions (n = 11). For each comparison is indicated the Pearson correlation coefficient along with the probability value for the null hypothesis of no correlation. (C) Kaplan-Meier curves of TTFT for subgroups of patients with CLL, defined by expression levels of catalase or GPX (n = 26). High and low enzyme expression values were referred to the median expression values. P values are from the logrank test.

Association of catalase or GPX levels with IGHV status, BCR signaling, and clinical behavior. (A) Expression levels of catalase or GPX in mutated (M) and unmutated (UM) IGHV CLL (n = 26). *P ≤ .05; **P ≤ .01 (B) Association between phosphorylation responses to BCR modulation and catalase or GPX expression levels. BCR signaling in response to anti-IgM stimulation was measured as the log2-fold change of ERK1/2 phosphorylation between anti-IgM-modulated and unmodulated conditions (n = 11). For each comparison is indicated the Pearson correlation coefficient along with the probability value for the null hypothesis of no correlation. (C) Kaplan-Meier curves of TTFT for subgroups of patients with CLL, defined by expression levels of catalase or GPX (n = 26). High and low enzyme expression values were referred to the median expression values. P values are from the logrank test.

Close Modal

or Create an Account

Close Modal
Close Modal